Gilead Sciences Inc.

2026-08-03 19:51; UTC

Gilead Sciences advances following a California Supreme Court ruling on HIV drug innovation, boosting investor sentiment ahead of Q2 earnings report.

2026-07-31 23:16; UTC

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

2026-07-30 21:31; UTC

Gilead Sciences shares are lower in after-market hours, continuing a decline since Thursday's close and remaining below the 20-day moving average.

2026-07-29 22:41; UTC

Gilead Sciences Inc shares are lower in after-market trading, with no specific news identified to explain the decline amid notable volatility earlier in the session.

2026-07-28 23:01; UTC

Gilead Sciences received endorsement for Trodelvy with Keytruda for specific breast cancer patients, boosting shares modestly higher in after-market trading.

2026-07-27 18:07; UTC

Morgan Stanley maintains Overweight rating on Gilead Sciences, lowering price target to $165. Shares are higher since Friday, supported by positive news on Trodelvy.

2026-07-24 21:41; UTC

Gilead Sciences receives positive CHMP opinion for Trodelvy and Keytruda combination, with shares rising in after-market trading despite broader market volatility.

2026-07-22 19:11; UTC

Gilead Sciences Inc is gaining Wednesday, having pulled back earlier in the session. Broader market sentiment is influenced by rising crude oil prices and geopolitical tensions.

2026-07-21 19:41; UTC

Gilead Sciences shares are lower after Leerink Partners downgraded the stock to Market Perform and cut the price target to $127 from $146.

2026-07-20 23:01; UTC

Gilead Sciences shares are lower in after-market hours following a downgrade from Leerink Partners, citing challenges in the HIV prophylaxis market and revised sales outlook.

2026-07-17 19:56; UTC

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

2026-07-16 23:41; UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

2026-07-15 18:46; UTC

Gilead Sciences Inc shares are higher, reflecting positive momentum in biotechnology amid a declining U.S. Dollar and easing inflation concerns.

2026-07-14 23:16; UTC

Gilead Sciences shares are higher in after-market trading, following a steady increase from earlier lows amid softer inflation data and a rally in Treasury bonds.

2026-07-13 17:26; UTC

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

2026-07-10 20:01; UTC

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

2026-07-09 19:36; UTC

Gilead Sciences Inc's shares are lower despite regulatory achievements for Trodelvy and advancements in its HIV pipeline, reflecting broader market volatility.

2026-07-08 23:51; UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

2026-07-07 23:02; UTC

Gilead Sciences Inc. shares are lower in after-market hours, reflecting broader market declines amid rising geopolitical tensions and a widening U.S. trade deficit.

2026-07-06 20:02; UTC

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2026-07-02 22:56; UTC

Gilead Sciences shares traded lower in after-market hours, with no specific news identified. Broader market mixed amid weaker U.S. jobless data.

2026-07-01 19:14; UTC

Gilead Sciences Inc. shares are lower today, reflecting routine performance within their one-month trading range despite stability around the midpoint.

2026-06-30 20:07; UTC

A social media post suggests bullish sentiment around Gilead Sciences, as a fund buys March call options. Shares are trading roughly flat in the session.

2026-06-29 23:06; UTC

Gilead Sciences Inc. shares are trading lower in after-market hours. Investor focus remains on upcoming U.S.-Iran talks that may impact market sentiment.

2026-06-26 22:11; UTC

Gilead Sciences Inc shares are lower in after-market hours, driven by notable declines in the Biotechnology sub-sector. No specific company news was identified.

2026-06-25 23:56; UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

2026-06-24 23:36; UTC

Gilead Sciences' Trodelvy receives FDA approval for first-line treatment of triple-negative breast cancer, boosting shares in after-market hours.

2026-06-23 23:56; UTC

European Commission approves Gilead's Trodelvy for triple-negative breast cancer, boosting shares higher in after-market hours amid notable intraday fluctuations.

2026-06-22 23:02; UTC

Gilead Sciences Inc shares are lower in after-market hours, reversing earlier gains and settling near the lower end of their one-month trading range.

2026-06-18 23:06; UTC

Gilead Sciences shares are lower in after-market trading, reflecting a decline since Thursday's close and nearing the lower end of their one-month range.